Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Gan To Kagaku Ryoho ; 43(3): 335-9, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27067850

ABSTRACT

Risk factors for hypokalemia were analyzed in patients who received anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MoAbs) at Gifu Municipal Hospital between February 2010 and March 2013. Subjects were 51 patients (27 men and 24 women) with the median age (interquartile range) of 66 (63-72) years. The study period started from the initiation of anti-EGFR MoAbs administration and ended 4 weeks after administration was completed. Patients were categorized into the side effect group if both minimum serum potassium (Min S-K) grade and b grade (pre-treatment S-K grade-Min S-K grade) were B1; otherwise, they were placed into the no side effect group. Univariate analysis for factors to prevent the side effect identified the "concomitant use of hyperkalemia-inducing drugs" to be statistically significant (p=0.010). Multivariate analysis was conducted on factors with a p value of <0.25 in the univariate analysis and on "concomitant use of hyperkalemia-inducing drugs," which was likely to clinically affect S-K decrease, although its p value was >0.25. It showed that "concomitant use of hyperkalemia-inducing drugs" was a significant risk-prevention factor (odds ratio: 0.138, 95% confidence interval[CI]: 0.033-0.581, p=0.007). In conclusion, "concomitant use of hyperkalemia-inducing drugs" is a factor associated with preventing hypokalemia accompanying anti-EGFR MoAbs administration.


Subject(s)
Antibodies, Monoclonal/adverse effects , ErbB Receptors/immunology , Hypokalemia/chemically induced , Neoplasms/drug therapy , Aged , Antibodies, Monoclonal/therapeutic use , Female , Humans , Male , Middle Aged , Neoplasm Staging , Neoplasms/pathology , Risk Factors
2.
Yakugaku Zasshi ; 133(11): 1223-33, 2013.
Article in Japanese | MEDLINE | ID: mdl-24189563

ABSTRACT

Since April 2011, a dosage adjustment program has been implemented at Gifu Municipal Hospital. In this program, upon receiving a prescription for renally eliminated drugs, pharmacists verify patients' serum creatinine concentrations by using a computerized medical record system to evaluate the patient's kidney function and suggest the appropriate dosage to doctors, if necessary. In our study, we used questionnaires that were administered to pharmacists and doctors at the hospital to investigate their respective working times and the cost of the program, in order to comprehensively analyze the clinical resource costs of the hospital and evaluate the economic burden of the program for levofloxacin. In addition, we studied the pharmacists' and doctors' attitudes toward the program and the circumstances of prescriptions for patients with renal dysfunction. The questionnaire comprised items such as time required for the program; attitude toward the program, including satisfaction; and attitude toward the circumstances of prescriptions for patients with renal dysfunction. The pharmacists' and doctors' working times and cost of the program were obtained from the questionnaire responses. For cost estimation, we used data from this study as well as those of our previous study that suggested that the levofloxacin program was economically beneficial. Furthermore, their attitudes toward the program and circumstances of prescriptions for patients with renal dysfunction were clarified. Regarding the pharmacists' tasks and interventions, we need to not only investigate attitudes toward them but also perform a cost analysis by the method of the economic evaluation of the medical techniques used in our study.


Subject(s)
Kidney Diseases/physiopathology , Levofloxacin/adverse effects , Dose-Response Relationship, Drug , Humans , Kidney Diseases/chemically induced , Kidney Function Tests , Levofloxacin/administration & dosage , Levofloxacin/economics , Surveys and Questionnaires
3.
Int Arch Allergy Immunol ; 137(2): 115-24, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15855793

ABSTRACT

BACKGROUND: A toluene-2,4-diisocyanate (TDI)-induced asthma model, in which delayed-type hypersensitivity-like asthmatic airway obstruction is elicited restrictively in the lung, has never been developed. METHODS: Guinea pigs were percutaneously sensitized with TDI. For the challenges, once every 2 weeks for a total of 5 times, TDI mists were delivered directly to the lung through an oral cannula, with its tip being positioned in the opening of the trachea. Time-course changes in specific airway resistance (sRaw) were measured by double-flow plethysmography. Basic mechanisms underlying TDI-induced asthma were analyzed. RESULTS: After the 2nd-5th challenges, induction of both an early increase in sRaw that peaked at 10 min and a delayed-type sRaw elevation that peaked at 22 h were observed. Interestingly, in the sensitized/challenged animals, baseline sRaw was elevated by repeated challenge as compared to that seen for non-sensitized animals. Intratracheal administration of a bronchodilator, salbutamol, strongly suppressed the early asthmatic response (EAR) but not the delayed-type asthmatic response (DAR). During DAR, both albumin leakage and fucose secretion into the bronchoalveolar lavage fluid were increased. The cysteinyl leukotriene antagonist pranlukast failed to inhibit either EAR or DAR while the corticosteroid dexamethasone significantly suppressed DAR, without significantly affecting EAR. CONCLUSIONS: Effective delivery of TDI to the lung may induce reproducible DAR in sensitized guinea pigs with chronicity that is reflected by an increase in the sRaw baseline. DAR is not mediated by constriction of airway smooth muscles and is probably due to the concurrent presence of mucosal edema and mucus hypersecretion in the airways.


Subject(s)
Asthma/chemically induced , Disease Models, Animal , Guinea Pigs , Hypersensitivity, Delayed/chemically induced , Toluene 2,4-Diisocyanate/toxicity , Airway Resistance , Albumins/metabolism , Albuterol/pharmacology , Allergens/immunology , Allergens/toxicity , Animals , Asthma/immunology , Chromones/pharmacology , Dexamethasone/pharmacology , Fucose/metabolism , Hypersensitivity, Delayed/immunology , Immunoglobulin E/metabolism , Immunoglobulin G/metabolism , Male , Time Factors , Toluene 2,4-Diisocyanate/immunology , Trachea
4.
J Pharmacol Sci ; 93(1): 47-54, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14501151

ABSTRACT

To develop an allergic dermatitis model showing persistent scratching in mice, toluene-2,4-diisocyanate (TDI) was repeatedly painted onto the skin of hairless HR-1 mice, and induction of itch-associated scratching behavior was observed. When HR-1 mice were epicutaneously sensitized with 1% TDI and then challenged by repeated painting the cervicodorsal skin with 0.1% TDI once every 10 days until the 10th challenge, delayed type scratching responses peaked at 1 - 2 days after challenge. TDI at 0.1% hardly induced scratching in non-sensitized HR-1 mice. The delayed scratching response was influenced by neither an H(1) nor 5-HT(1/2) receptor antagonist. On the other hand, intradermal injection of histamine and serotonin induced frequent scratching in HR-1 mice. In conclusion, repeated application of TDI can induce delayed type allergic scratching. Although HR-1 mice are high responders to both histamine and serotonin, induction of the delayed response depends on neither of these chemical mediators. This delayed response may be useful in analyzing the mechanisms of allergic pruritus.


Subject(s)
Dermatitis, Allergic Contact/physiopathology , Pruritus/physiopathology , Toluene 2,4-Diisocyanate/toxicity , Animals , Male , Mice , Mice, Hairless , Mice, Inbred ICR , Pruritus/chemically induced , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...